- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05419466
Kinetic of Compounds of a Melatonin-based Formulation in Healthy Subjects
April 3, 2023 updated by: Larena SAS
Kinetic of Plasmatic Compounds and Metabolites of a Melatonin-based Formulation in Healthy Subjects
This study is conducted to clinically document the melatonin and zinc bioavailability of a dietary supplement containing delayed release melatonin, zinc and lemon balm
Study Overview
Status
Recruiting
Conditions
Study Type
Interventional
Enrollment (Anticipated)
14
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Dijon, France, 21000
- Recruiting
- Cen Experimental
-
Contact:
- Carole PERRIN
- Phone Number: 03 80 68 05 05
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Male between the ages of 18 and 45,
- In good general health, i.e., free of chronic conditions and not taking medication at the time of inclusion and/or long-term,
- Over 70 kg and with a body mass index between 18.5 and 24.9,
- Able and willing to participate in the research by complying with the procedures of the protocol, in particular concerning the taking of the product under study and the performance of sequential blood tests,
- Having freely signed the consent form after adequate information on the proposed study,
- Affiliated to a social security scheme or similar.
Exclusion Criteria:
- Smoker,
- Drug addict,
- Subject with an alcohol consumption of more than 2 glasses per day,
- Taking a drug treatment or melatonin or zinc or a product containing it within 48 hours prior to a kinetics visit,
- Known organic or functional abnormality of the urinary tree,
- Any medical condition that would involve a change in melatonin metabolism: Drug intake: Fluvoxamine, 5- or 8-methoxypsoralen, cimetidine, carbamazepine, rifampicin, analgesics, Liver abnormality known or detected at the screening visit and judged to be clinically significant by the investigator, Known autoimmune disease,
- Any condition that could involve zinc deficiency or hyperzincemia: Medication intake: penicillamine or diuretics, Poisoning by exposure to zinc (zinc mines, zinc metallurgy, galvanizing operations, manufacture of alloys, use of zinc-based pigments and salts, etc.), Pick's disease, malabsorption (pancreatic insufficiency, biliary obstruction, gastrectomy, jejuno-ileostomy, intestinal diverticulum, tropical sprue, celiac disease, cystic fibrosis), intestinal inflammation (enteropathy with protein leakage, inflammatory colitis), liver disorders (cirrhosis, hepatitis) , kidney disorders (chronic renal failure, nephrotic syndrome), neuropsychiatric disorders (anorexia nervosa, endogenous depression, alcoholism), genetic diseases (acrodermatitis enteropathica, thalassemia, sickle cell disease, diabetes, trisomy 21, phenylketonuria), parasitic diseases (ankylostomiasis, schistosomiasis, malaria , giardiasis)
- Subject assessed as "rather" or "definitely" among evening people,
- Epileptic subject,
- Asthmatic subject,
- Known hypertension (>140/90),
- Diagnosis of migraine by a health professional according to the International Headache Society (IHS) criteria revised in 2004,
- With a sleep disorder,
- Thyroid dysfunction, hyperglycemia or anemia judged to be clinically significant by the investigator,
- Blood donation within one month prior to inclusion,
- A known organic or psychological abnormality (including a history of severe depression) that may bias the results of the study as judged by the investigator,
- Workers with atypical working hours (night work, staggered working hours),
- Known allergy or intolerance to any of the components of the product,
- Psychological or linguistic inability to understand and sign informed consent,
- Participant in another interventional clinical trial or during a period of exclusion from a previous clinical trial,
- Under legal protection (guardianship, curatorship) or deprived of his rights as a result of the administrative or judicial decision,
- Subject who has reached the maximum threshold for compensation for research provided for in the regulations.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: melatonin and zinc bioavailability
dietary supplement, 1 tablet containing delayed release melatonin, zinc and lemon balm
|
dietary supplement is dosed at 1.9 mg of melatonin, 10 mg of zinc and 200 mg of lemon balm for one tablet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evolution of the plasma melatonin concentration
Time Frame: Up to 720 minutes after taking the tablet
|
The change in plasma melatonin concentration
|
Up to 720 minutes after taking the tablet
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma melatonin AUC
Time Frame: Up to 720 minutes after taking the tablet
|
Area Under the Curve of plasma melatonin
|
Up to 720 minutes after taking the tablet
|
Plasma melatonin Cmax
Time Frame: Up to 720 minutes after taking the tablet
|
Peak concentration of plasma melatonin
|
Up to 720 minutes after taking the tablet
|
Plasma melatonin Tmax
Time Frame: Up to 720 minutes after taking the tablet
|
Time take to reach Cmax of plasma melatonin
|
Up to 720 minutes after taking the tablet
|
Plasma melatonin half life
Time Frame: Up to 720 minutes after taking the tablet
|
Time required for the concentration of plasma melatonin to decrease to half of its starting dose
|
Up to 720 minutes after taking the tablet
|
Evolution of the plasma concentration of 6-sulfatoxymelatonin
Time Frame: Up to 720 minutes after taking the tablet
|
The change in plasma 6-sulfatoxymelatonin concentration
|
Up to 720 minutes after taking the tablet
|
Plasma 6-sulfatoxymelatonin AUC
Time Frame: Up to 720 minutes after taking the tablet
|
Area Under the Curve of plasma 6-sulfatoxymelatonin
|
Up to 720 minutes after taking the tablet
|
Plasma 6-sulfatoxymelatonin Cmax
Time Frame: Up to 720 minutes after taking the tablet
|
Peak concentration of plasma 6-sulfatoxymelatonin
|
Up to 720 minutes after taking the tablet
|
Plasma 6-sulfatoxymelatonin Tmax
Time Frame: Up to 720 minutes after taking the tablet
|
Time take to reach Cmax of plasma 6-sulfatoxymelatonin
|
Up to 720 minutes after taking the tablet
|
Plasma 6-sulfatoxymelatonin half life
Time Frame: Up to 720 minutes after taking the tablet
|
Time required for the concentration of plasma 6-sulfatoxymelatonin to decrease to half of its starting dose
|
Up to 720 minutes after taking the tablet
|
Evolution of the plasma zinc concentration
Time Frame: Up to 720 minutes after taking the tablet
|
The change in plasma zinc concentration
|
Up to 720 minutes after taking the tablet
|
Plasma zinc AUC
Time Frame: Up to 720 minutes after taking the tablet
|
Area Under the Curve of plasma zinc
|
Up to 720 minutes after taking the tablet
|
Plasma zinc Cmax
Time Frame: Up to 720 minutes after taking the tablet
|
Peak concentration of plasma zinc
|
Up to 720 minutes after taking the tablet
|
Plasma zinc Tmax
Time Frame: Up to 720 minutes after taking the tablet
|
Time take to reach Cmax of plasma zinc
|
Up to 720 minutes after taking the tablet
|
Plasma zinc half life
Time Frame: Up to 720 minutes after taking the tablet
|
Time required for the concentration of plasma zinc to decrease to half of its starting dose
|
Up to 720 minutes after taking the tablet
|
Evolution of state of drowsiness
Time Frame: Up to 720 minutes after taking the tablet
|
The change in (Visual Analog Scale)VAS score, minimum = 0 and maximum = 10 higher score means a worse outcome
|
Up to 720 minutes after taking the tablet
|
Adverse events
Time Frame: During study participation, maximum 45 days
|
Number and type of adverse events
|
During study participation, maximum 45 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 14, 2023
Primary Completion (Anticipated)
June 30, 2023
Study Completion (Anticipated)
June 30, 2023
Study Registration Dates
First Submitted
June 3, 2022
First Submitted That Met QC Criteria
June 10, 2022
First Posted (Actual)
June 15, 2022
Study Record Updates
Last Update Posted (Actual)
April 5, 2023
Last Update Submitted That Met QC Criteria
April 3, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C1711
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Melatonin Bioavailability
-
PiLeJeCompletedMelatonin BioavailabilityFrance
-
Khon Kaen UniversityUnknownPharmacokinetics of MelatoninThailand
-
VA Palo Alto Health Care SystemCompleted
-
Brigham and Women's HospitalNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedCircadian Rhythm | Melatonin | Glucose | GenesUnited States
-
Dennis Bregner ZetnerHerlev Hospital; Copenhagen University Hospital, Denmark; RepoCeuticals ApSCompletedPharmacokinetics | Safety | MelatoninDenmark
-
Brigham and Women's HospitalNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedCircadian Rhythm | Melatonin | Glucose | Genes | LightUnited States
-
Initiator PharmaNot yet recruiting
-
Fundació EurecatURIACH, S.L.Completed
-
WockhardtCompletedBioavailabilityUnited States
-
Midwest Center for Metabolic and Cardiovascular...NaturmegaCompleted
Clinical Trials on dietary supplement, 1 tablet containing delayed release melatonin, zinc and lemon balm
-
PiLeJeCompletedMelatonin BioavailabilityFrance